Medicare Compliance & Reimbursement

Pharmaceuticals:

Demo Covers Recurrent Breast Cancer Drugs

 Officials say there's lots of spots left in demo.

Medicare has expanded the coverage guidelines for providers participating in one of its drug demonstration projects.
 
The Medicare Replacement Drug Demonstration project will cover drugs for all patients with recurrent breast cancer, as well as patients with breast cancer of stage two to four, CMS officials revealed at Medicare's June 7 Physician Open Door Forum.
 
The demonstration has enrolled over 29,000 people but still has lots of room for more, CMS officials said.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Medicare Compliance & Reimbursement

View All